23:26 , Nov 13, 2018 |  BC Extra  |  Company News

Management tracks: Anchiano, ContraFect

Cancer company Anchiano Therapeutics Inc. (Tel Aviv:ANCN) appointed Stephen Hoffman chairman. He is CEO of Aerpio Pharmaceuticals Inc. (OTCQB:ARPO). Anchiano also named Robert Connelly a director. He was a venture partner at Flagship Pioneering and...
18:11 , Jul 27, 2018 |  BC Week In Review  |  Financial News

With Ex-Receptos execs at helm, Gossamer raises another large round

Gossamer Bio Inc. (San Diego, Calif.) raised $230 million on July 23 in an untranched series B round led by new investor Hillhouse Capital, bringing the biotech's total funding to $330 million since its January...
20:21 , Jul 23, 2018 |  BC Extra  |  Financial News

Ex-Receptos team snags another big round at Gossamer

Gossamer Bio Inc. (San Diego, Calif.) raised $230 million in an untranched series B round led by new investor Hillhouse Capital, bringing the biotech's total funding to $330 million since its January launch. Also participating...
00:51 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Bleeding Patient sample and mouse studies suggest HIF1A stabilizers could help treat heavy menstrual bleeding. In endometrial samples from patients, levels of HIF1A were lower than in patients with normal menstrual bleeding. In a...
23:25 , Nov 15, 2017 |  BC Extra  |  Company News

Management tracks: Outpost, Torque

Genitourinary play Outpost Medicine LLC (Indianapolis, Ind.) named Scott Byrd president and CEO. He succeeds interim CEO David Socks, who will remain on the company's board. Byrd was president and COO at the Acacia Pharma...
20:46 , Nov 10, 2017 |  BC Week In Review  |  Financial News

Invirsa raises $520K in seed round

Infectious disease play Invirsa Inc. (Columbus, Ohio) raised $520,000 in a seed financing led by CincyTech. Initial investor Rev1 Ventures also participated. Invirsa's lead candidate, INV-102, is in preclinical testing to treat acute conjunctivitis and...
16:50 , Oct 17, 2017 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Glaucoma Mouse studies suggest activating Tie2 could help treat primary open-angle glaucoma (POAG). In a mouse model of POAG, intraocular injection of a Tie2-activating antibody decreased intraocular pressure compared with a control antibody. Next...
23:22 , Oct 11, 2017 |  BC Extra  |  Company News

Management tracks: Aerpio, Scancell, TCR2

Ophthalmic company Aerpio Pharmaceuticals Inc. (OTCQB:ARPO) named Stephen Hoffman CEO, effective Dec. 1, 2017. He succeeds Aerpio founder Joseph Gardner, who will remain its president. Hoffman was a senior advisor at PDL BioPharma Inc. (NASDAQ:PDLI),...
06:13 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

Aerpio begins Phase IIb of AKB-9778 in diabetic retinopathy

Aerpio Pharmaceuticals Inc. (Cincinnati, Ohio) began the Phase IIb TIME-2b trial to evaluate once- and twice-daily 15 mg subcutaneous AKB-9778 for 12 months in about 150 patients with moderate to severe non-proliferative diabetic retinopathy. The...
17:39 , Mar 17, 2017 |  BC Week In Review  |  Financial News

Aerpio Pharmaceuticals completes venture financing

On March 16, ophthalmology company Aerpio Pharmaceuticals Inc. (Cincinnati, Ohio) raised $40 million in a venture financing. New investors Montrose Capital Partners and Ally Bridge Group and existing investors Novartis Venture Fund, OrbiMed, Satter Investment...